A little more than a year after reorganizing the company and slashing staff in the wake of a Phase III failure, Ann Arbor, MI-based Aastrom Biosciences has acquired Sanofi’s cell therapy and regenerative medicine business for the low, low purchase price of $6.5 million–$4 million payable in cash and $2.5 million in a promissory note.

…read more

Source: Aastrom surges after acquiring Sanofi’s cell therapies


0 No comments